XML 65 R53.htm IDEA: XBRL DOCUMENT
v3.25.1

Research, Consulting and Supply Agreements (Details Narrative) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) Integer | Dec. 31, 2022 USD ($) | Sep. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Mar. 31, 2025 USD ($) | Mar. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2017 Integer | Oct. 31, 2023 USD ($) shares
Research and development expense |  |  |  |  |  | $ 1,080,000 | $ 1,951,000 |  |  |
Amarex Clinical Research LLC [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 105,000 | 521,000 |  |  |
Research and development expense excluding acquired in process cost |  |  |  | $ 6,400,000 | $ 8,400,000 |  |  |  |  |
Development cost |  |  |  | 125,000 | $ 1,000,000 |  |  | $ 6,600,000 |  |
Invigilators cost |  |  |  | $ 4,400,000 |  |  |  |  |  |
Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 3,000 | 86,000 |  |  |
Amarex Clinical Research LLC [Member] | Post COVID [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 102,000 | 435,000 |  |  |
Jubilant HollisterStier [Member] |  |  |  |  |  |  |  |  |  |
Development cost |  | $ 1,432,000 |  |  |  |  |  |  |  |
Number of units manufactured | Integer |  |  |  |  |  |  |  |  | 16,000 |
Additional number of vials | Integer |  | 27,900 |  |  |  |  |  |  |  |
Jubilant HollisterStier [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 0 | 1,000,000 |  |  |
Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  | 129,000 |  |  |
Erasmus [Member] | Joint Clinical Study Agreement [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  | $ 200,000 |  |  |  |  |  |  |
Erasmus [Member] | Jjoint Clinical Study Agreement [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  | 4,000 |  |  |
Azenova Sales International [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 15,000 | 90,000 |  |  |
Stock options, aggregate intrinsic value |  |  |  |  |  |  |  |  |  | $ 30,000
Stock options, vested | shares |  |  |  |  |  |  |  |  |  | 360,000
Alcami [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense | $ 30,000 |  |  |  |  | 7,000 | $ 10,000 |  |  |
Clinical Studies [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 594,000 |  |  |  |
Manufacturing and Engineering [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 180,000 |  |  |  |
Quality Control [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 230,000 |  |  |  |
Regulatory [Member] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | $ 76,000 |  |  |  |

X
- Definition Number of vials. + References No definition available. + Details
Name: | AIMI_NumberOfVials
Namespace Prefix: | AIMI_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Units manufactured. + References No definition available. + Details
Name: | AIMI_UnitsManufactured
Namespace Prefix: | AIMI_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 932 -SubTopic 360 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 932 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-10(c)(7)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1 + Details
Name: | us-gaap_DevelopmentCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=AIMI_AmarexClinicalResearchLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_PancreaticCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_PostCOVIDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_JubilantHollisterStierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_ResearchConsultingAndSupplyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_PharmaSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_MasterServiceAgreementAndQualityAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_ErasmusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_JointClinicalStudyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_JjointClinicalStudyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_AzenovaSalesInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_AlcamiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_ClinicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_ManufacturingAndEngineeringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_QualityControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_RegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |